[go: up one dir, main page]

MX2008009592A - Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. - Google Patents

Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.

Info

Publication number
MX2008009592A
MX2008009592A MX2008009592A MX2008009592A MX2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A
Authority
MX
Mexico
Prior art keywords
methods
ovarian cancer
analysis
biomarkers
identify patients
Prior art date
Application number
MX2008009592A
Other languages
English (en)
Inventor
Timothy J Fischer
Clark M Whitehead
Douglas P Malinowski
Qin He
Robert L Cheek
John W Groelke
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of MX2008009592A publication Critical patent/MX2008009592A/es

Links

Classifications

    • G01N33/575—
    • G01N33/57545—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan métodos de análisis para Identificar pacientes con una probabilidad incrementada de tener cáncer de ovario. Los métodos de análisis involucran te detección de la expresión de una pluralidad de biomarcadores en una muestra corporal, en donde la sobre- expresión de los biomarcadores es indicativa de una probabilidad incrementada de tener cáncer de ovario. Los métodos de análisis además pueden comprender un análisis de dos etapas. Los biomarcadores de interés incluyen genes y proteínas que están, por ejemplo, involucradas en la replicación de ADN/control del ciclo celular, crecimiento celular y proliferación, escape de apoptósis, angiogénesis o linfogénesis o los mecanismos de la motilidad e invasión celular cancerosa. En algunos aspectos de la invención, la expresión de un biomarcador está detectada en el nivel de proteína usando un anticuerpo biomarcador-específico o en el nivel del ácido nucleico usando las técnicas de hibridación de ácido nucleico. Los métodos para detectar el cáncer de ovario en los pacientes además se describe en este documento. También se proporcionan los equipos para practicar los métodos de la invención.
MX2008009592A 2006-01-27 2007-01-29 Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. MX2008009592A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76276006P 2006-01-27 2006-01-27
PCT/US2007/061205 WO2007090076A2 (en) 2006-01-27 2007-01-29 Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor

Publications (1)

Publication Number Publication Date
MX2008009592A true MX2008009592A (es) 2008-09-08

Family

ID=38328113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009592A MX2008009592A (es) 2006-01-27 2007-01-29 Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.

Country Status (11)

Country Link
US (3) US20070212721A1 (es)
EP (2) EP1987360B1 (es)
JP (1) JP2009524438A (es)
KR (1) KR20080094803A (es)
CN (1) CN101410715A (es)
AT (1) ATE548656T1 (es)
AU (1) AU2007211085A1 (es)
BR (1) BRPI0707249A2 (es)
CA (1) CA2637446A1 (es)
MX (1) MX2008009592A (es)
WO (1) WO2007090076A2 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741019B2 (en) * 2000-11-01 2010-06-22 Mount Sinai Hospital Detection of ovarian cancer
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
JP2009526519A (ja) * 2006-01-17 2009-07-23 セルーメン、インコーポレイテッド 生物学的システム応答の予測方法
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
ATE540750T1 (de) 2006-05-11 2012-01-15 Raindance Technologies Inc Mikrofluidische vorrichtung und verfahren
JP5406019B2 (ja) 2006-05-17 2014-02-05 セルーメン、インコーポレイテッド 自動化組織分析のための方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
AU2007253740A1 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
WO2007139895A2 (en) * 2006-05-24 2007-12-06 Cellumen, Inc. Method for modeling a disease
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
WO2008060483A2 (en) * 2006-11-10 2008-05-22 Cellumen, Inc. Protein-protein interaction biosensors and methods of use thereof
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008112514A1 (en) * 2007-03-09 2008-09-18 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20090087849A1 (en) * 2007-09-06 2009-04-02 Tripath Imaging, Inc. Nucleic acid-based methods and compositions for the detection of ovarian cancer
US20090130195A1 (en) * 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
EP2088204A1 (en) * 2008-02-05 2009-08-12 Adnagen AG Method and kit for diagnosing or controlling the treatment of ovarian cancer
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
EP2350917A4 (en) * 2008-10-06 2012-06-06 Somalogic Inc Ovarian cancer biomarkers and uses thereof
JP5684724B2 (ja) * 2008-12-30 2015-03-18 ヤンセン バイオテツク，インコーポレーテツド 強直性脊椎炎を有する患者における抗−ＴＮＦα抗体に対する臨床応答を予測する血清マーカー
EP2403880A1 (en) 2009-03-05 2012-01-11 Tripath Imaging, Inc. Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010102177A1 (en) 2009-03-06 2010-09-10 Becton, Dickinson And Company Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
US8528589B2 (en) 2009-03-23 2013-09-10 Raindance Technologies, Inc. Manipulation of microfluidic droplets
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
WO2011100453A2 (en) * 2010-02-10 2011-08-18 Maine Medical Center Compositions and methods for the treatment of cardiac and vascular disease
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP2591357A4 (en) 2010-07-09 2014-01-01 Somalogic Inc Lung cancer biomarkers and uses thereof
WO2012021795A2 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
EP2659005A4 (en) * 2010-12-28 2016-08-24 Caris Mpi Inc MOLECULAR PROFILING OF CANCER
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
ES2834617T3 (es) * 2011-02-17 2021-06-18 Fujirebio Diagnostics Inc Composiciones y métodos de uso para la determinación de HE4a
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
CA2828119A1 (en) * 2011-02-24 2012-08-30 Vermillion, Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
AU2012229102B2 (en) 2011-03-17 2016-02-04 Cernostics, Inc. Systems and compositions for diagnosing Barrett's esophagus and methods of using the same
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012142330A1 (en) * 2011-04-15 2012-10-18 Brown University Micro rnas as diagnostic biomarkers and therapeutics for ovarian cancer and metastatic tumors that disseminate within the peritoneal cavity
EP3216872B1 (en) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
BR112013031019A2 (pt) * 2011-06-02 2017-03-21 Almac Diagnostics Ltd teste diagnóstico molecular para câncer
EP2721417A4 (en) * 2011-06-17 2015-05-06 Univ Arkansas NEW MARKERS FOR EARLY DIAGNOSIS OF EGG CANCER, MONITORING DURING THE CORRESPONDING THERAPY AND NEW THERAPY OPTIONS DURING AND AFTER THE CORRESPONDING CHEMOTHERAPY
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP3495817B1 (en) 2012-02-10 2024-10-16 Bio-Rad Laboratories, Inc. Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
AU2013353839A1 (en) 2012-12-03 2015-06-18 Almac Diagnostics Limited Molecular diagnostic test for cancer
CN105264374A (zh) * 2013-03-27 2016-01-20 赛拉诺斯股份有限公司 用于样品分析的方法、装置和系统
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP3047277B1 (en) * 2013-09-18 2018-11-21 Adelaide Research & Innovation Pty Ltd. Autoantibody biomarkers of ovarian cancer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US11221327B2 (en) * 2013-10-10 2022-01-11 Mcmaster University Method for diagnosing and monitoring inflammatory disease progression
CN103525941A (zh) * 2013-10-29 2014-01-22 上海市奉贤区中心医院 Cthrc1基因在制备检测/治疗宫颈癌药物中的应用
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CN111718413A (zh) * 2015-06-26 2020-09-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
AU2016359685B2 (en) 2015-11-25 2022-12-22 Cernostics, Inc. Methods of predicting progression of Barrett's esophagus
JP2019515265A (ja) * 2016-04-20 2019-06-06 エーザイ インク． バイオマーカーを使用する漿液性卵巣がんの予後
GB2566221B (en) * 2016-06-24 2021-08-04 Univ South Carolina Inhibin as targetable regulators of angiogenesis
WO2018009811A1 (en) * 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
EP3504553B1 (en) * 2016-08-10 2022-04-20 Memed Diagnostics Ltd. System and method for analysis of biological data
CN106520924A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测卵巢癌的引物组及检测方法
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
CN112946290A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 细胞外基质底物反应蛋白1在制备诊断和预测卵巢癌试剂中的应用
KR102316178B1 (ko) * 2020-04-14 2021-10-22 서울대학교병원 난소암 환자의 암 재발율 또는 생존율 예측용 조성물
CN111693703B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Spondin 1和HE4联合用作早期卵巢癌生物标志物以及试剂盒
KR102472050B1 (ko) * 2022-03-29 2022-11-30 주식회사 아이엠비디엑스 환자 맞춤형 패널을 이용한 암의 재발을 예측하는 방법

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
CA1340288C (en) 1988-09-02 1998-12-29 Robert Charles Ladner Generation and selection of novel binding proteins
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
EP1086742B2 (en) 1991-11-22 2007-03-14 Affymetrix, Inc. (a Delaware Corporation) Combinatorial strategies for polymer synthesis
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
HUP0003986A3 (en) 1997-10-14 2001-04-28 Luminex Corp Austin Precision fluorescently dyed particles and methods of making and using same
US6033860A (en) 1997-10-31 2000-03-07 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6268222B1 (en) 1998-01-22 2001-07-31 Luminex Corporation Microparticles attached to nanoparticles labeled with flourescent dye
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US7223727B2 (en) * 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
AU3897999A (en) 1998-05-14 1999-11-29 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020151681A1 (en) * 1999-03-12 2002-10-17 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20030064072A9 (en) * 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020019330A1 (en) * 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040009494A1 (en) * 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20020015970A1 (en) * 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
WO2001021653A2 (en) * 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030171252A9 (en) * 2000-01-31 2003-09-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020086330A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090615A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020086823A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020077270A1 (en) * 2000-01-31 2002-06-20 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020061521A1 (en) * 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030092611A9 (en) * 2000-01-31 2003-05-15 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020094953A1 (en) * 2000-01-31 2002-07-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040101927A9 (en) * 2000-01-31 2004-05-27 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090674A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
US20020045230A1 (en) * 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002023201A2 (en) * 2000-09-13 2002-03-21 Zymogenetics, Inc. Use of human phermone polypeptides
US20020182619A1 (en) * 2000-11-08 2002-12-05 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
AU2002254615A1 (en) * 2001-04-17 2002-10-28 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
IL158397A0 (en) * 2001-04-18 2004-05-12 Genset Sa Polypeptides, their preparation and their use
AU2002344326A1 (en) * 2001-05-11 2002-11-25 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US7205142B2 (en) * 2001-05-11 2007-04-17 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
IL159015A0 (en) * 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) * 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
ES2346202T3 (es) * 2002-08-06 2010-10-13 The Johns Hopkins University Uso de biomarcadores para detectar cancer.
EP1570078A4 (en) * 2002-10-04 2006-09-13 Van Andel Res Inst MOLECULAR CLASSIFICATION OF RENAL TUMORS AND DISCOVERING NEW DIAGNOSTIC MARKERS
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
US20050208500A1 (en) * 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
FR2855832B1 (fr) * 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20070037204A1 (en) * 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
WO2005016126A2 (en) * 2003-08-15 2005-02-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Multifactorial assay for cancer detection
EP1668149A4 (en) * 2003-09-05 2007-01-03 Royal Women S Hospital DIAGNOSTIC MARKER FOR OVARIAN CARCINOMA
EP1670350A4 (en) * 2003-10-07 2008-02-13 Millennium Pharm Inc NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF OVARIAL CANCER
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
EP1766408A2 (en) * 2004-07-09 2007-03-28 Tripath Imaging, Inc. Methods and compositions for the detection of ovarian cancer
ES2650244T3 (es) * 2006-01-04 2018-01-17 Fujirebio America, Inc. Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres endometriales y uterinos

Also Published As

Publication number Publication date
US20090075307A1 (en) 2009-03-19
US20070212721A1 (en) 2007-09-13
CA2637446A1 (en) 2007-08-09
CN101410715A (zh) 2009-04-15
WO2007090076A2 (en) 2007-08-09
JP2009524438A (ja) 2009-07-02
ATE548656T1 (de) 2012-03-15
WO2007090076A8 (en) 2011-03-03
EP1987360B1 (en) 2012-03-07
US20090068690A1 (en) 2009-03-12
EP1987360A2 (en) 2008-11-05
EP2363711A1 (en) 2011-09-07
AU2007211085A1 (en) 2007-08-09
KR20080094803A (ko) 2008-10-24
WO2007090076A3 (en) 2007-11-08
BRPI0707249A2 (pt) 2011-04-26

Similar Documents

Publication Publication Date Title
MX2008009592A (es) Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
ES2530734T3 (es) Biomarcador en suero bioquímico
DK1668368T3 (da) Detektion af histon-modifikation i cellefrie nukleosomer
ATE431854T1 (de) Auf bio-barcodes beruhender nachweis von zielanalyten
ATE536553T1 (de) Verfahren zum nachweis grösserer ungünstiger kardiovaskulärer und zerebrovaskulärer ereignisse
Leung et al. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies
CY1112553T1 (el) Ανοσοπροσδιορισμοι υψηλης ευαισθησιας και κιτια για τον προσδιορισμο πεπτιδιων και πρωτεϊνων βιολογικου ενδιαφεροντος
DE602004015626D1 (de) Bei brustkrebs
WO2016198833A3 (en) Methods for analysing a urine sample
EA201691496A1 (ru) Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток
ES2638294T3 (es) Método de detección de cáncer
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
BR112019007081A2 (pt) sistema de análise e método para testagem de uma amostra
ES2863274T3 (es) Biomarcador de muerte celular
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
MX2024008021A (es) Secuenciacion de ultima generacion para la medicion de proteinas.
DE602005014386D1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
EA201300008A1 (ru) Недорогие электродные чипы (варианты) и способы многокомпонентного анализа и оценки на основе катодной электролюминесценции
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
ES2530574T3 (es) Biomarcadores asociados a la nefropatía
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
WO2013003216A4 (en) Methods for determining response to neoadjuvant therapy and survival using microrna-10b

Legal Events

Date Code Title Description
FA Abandonment or withdrawal